{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T14:25:19Z","timestamp":1783952719068,"version":"3.55.0"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T00:00:00Z","timestamp":1759190400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T00:00:00Z","timestamp":1759190400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Roche Pharmaceuticals A\/S","award":["Roche Pharmaceuticals A\/S"],"award-info":[{"award-number":["Roche Pharmaceuticals A\/S"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Health Econ"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1007\/s10198-025-01843-x","type":"journal-article","created":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T10:11:44Z","timestamp":1759227104000},"page":"571-580","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Total costs of different lines of treatment in diffuse large B-cell lymphoma in Denmark \u2013 a real-world data analysis"],"prefix":"10.1007","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-8898-4707","authenticated-orcid":false,"given":"Christian Graves","family":"Beck","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin Lucas","family":"J\u00f8rgensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maya Friis","family":"Kjaergaard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S\u00f8ren Ramme","family":"Bro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tove","family":"Holm-Larsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,9,30]]},"reference":[{"issue":"1","key":"1843_CR1","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.canep.2014.12.001","volume":"39","author":"Y Li","year":"2015","unstructured":"Li, Y., Wang, Y., Wang, Z., Yi, D., Ma, S.: Racial differences in three major NHL subtypes: Descriptive epidemiology. Cancer Epidemiol 39(1), 8\u201313 (2015). https:\/\/doi.org\/10.1016\/j.canep.2014.12.001","journal-title":"Cancer Epidemiol"},{"issue":"20","key":"1843_CR2","doi-asserted-by":"publisher","first-page":"2375","DOI":"10.1182\/blood-2016-01-643569","volume":"127","author":"S Swerdlow","year":"2016","unstructured":"Swerdlow, S., Campo, E., Pileri, S., Harris, N., Stein, H., Siebert, R., et al.: The 2016 revision of the world health organization classification of lymphoid neoplasms. Blood 127(20), 2375\u20132390 (2016). https:\/\/doi.org\/10.1182\/blood-2016-01-643569","journal-title":"Blood"},{"issue":"2","key":"1843_CR3","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1007\/s40487-024-00265-8","volume":"12","author":"S Pacis","year":"2024","unstructured":"Pacis, S., Bolzani, A., Heuck, A., Gossens, K., Kruse, M., Fritz, B., et al.: Epidemiology and Real-World treatment of incident diffuse large B-cell lymphoma (DLBCL): A German claims data analysis. Oncol. Ther 12(2), 293\u2013309 (2024). https:\/\/doi.org\/10.1007\/s40487-024-00265-8","journal-title":"Oncol. Ther"},{"key":"1843_CR4","unstructured":"Diffust storcellet B-celle lymfom. Version 3.0. 5: Sekretariatet for Kliniske Retningslinjer p\u00e5 Kr\u00e6ftomr\u00e5det (2023). https:\/\/www.dmcg.dk\/siteassets\/kliniske-retningslinjer---skabeloner-og-vejledninger\/kliniske-retningslinjer-opdelt-pa-dmcg\/dlg\/dlg_storcelle-diffet-b-celle-lymfom_v.3.0_admgodk051223.pdf)"},{"key":"1843_CR5","doi-asserted-by":"publisher","unstructured":"Gang, A., Str\u00f8m, C., Pedersen, M., d\u2019Amore, F., Pedersen, L., Bukhet, A.: al. R-CHOEP-14 improves overall survival in young high-risk patients with diffuse large B-cell lymphoma compared with R-CHOP-14. A population-based investigation from the Danish Lymphoma Group. Ann Oncol. 23(1), 147\u2013153 Https:\/\/ (2012). https:\/\/doi.org\/10.1093\/annonc\/mdr058","DOI":"10.1093\/annonc\/mdr058"},{"issue":"2","key":"1843_CR6","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1002\/ajh.27151","volume":"99","author":"D Al-Sarayfi","year":"2024","unstructured":"Al-Sarayfi, D., Brink, M., Chamuleau, M., Brouwer, R., van Rijn, R., Issa, D., et al.: R-miniCHOP versus R-CHOP in elderly patients with diffuse large B-cell lymphoma: A propensity matched population-based study. Am. J. Hematol. 99(2), 216\u2013222 (2024). https:\/\/doi.org\/10.1002\/ajh.27151","journal-title":"Am. J. Hematol."},{"issue":"27","key":"1843_CR7","doi-asserted-by":"publisher","first-page":"4184","DOI":"10.1200\/JCO.2010.28.1618","volume":"28","author":"C Gisselbrecht","year":"2010","unstructured":"Gisselbrecht, C., Glass, B., Mounier, N., et al.: Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era. Journal of Clinical Oncology 28(27), 4184\u20134190 (2010). https:\/\/doi.org\/10.1200\/JCO.2010.28.1618","journal-title":"Journal of Clinical Oncology"},{"issue":"Supplement 1","key":"1843_CR8","doi-asserted-by":"publisher","first-page":"12106","DOI":"10.1182\/blood-2022-169045","volume":"140","author":"M Garg","year":"2022","unstructured":"Garg, M., Takyar, J., Dhawan, A., Saggu, G., Agrawal, N., Hall, A., et al.: Diffuse large B-Cell lymphoma (DLBCL): A structured literature review of the Epidemiology, treatment Guidelines, and Real-World treatment patterns. Blood. 140(Supplement 1), 12106\u201312107 (2022). https:\/\/doi.org\/10.1182\/blood-2022-169045","journal-title":"Blood"},{"issue":"3","key":"1843_CR9","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1111\/bjh.19201","volume":"204","author":"A Al-Mashhadi","year":"2023","unstructured":"Al-Mashhadi, A., Jakobsen, L., Brown, P., Gang, A., Thorsteinsson, A., Rasoul, K., et al.: Real-world outcomes following third or subsequent lines of therapy: A Danish population-based study on 189 patients with relapsed\/refractory large B-cell lymphomas. Br. J. Haematol. 204(3), 839\u2013848 (2023). https:\/\/doi.org\/10.1111\/bjh.19201","journal-title":"Br. J. Haematol."},{"issue":"1","key":"1843_CR10","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1007\/s40487-022-00211-6","volume":"11","author":"P Borchmann","year":"2023","unstructured":"Borchmann, P., Heger, J., Mahlich, J., Papadimitrious, M., Riou, S., Werner, B.: Healthcare resource utilization and associated costs of German patients with diffuse large B-Cell lymphoma: A retrospective health claims data analysis. Oncol. Ther. 11(1), 65\u201381 (2023). https:\/\/doi.org\/10.1007\/s40487-022-00211-6","journal-title":"Oncol. Ther."},{"issue":"7","key":"1843_CR11","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1016\/j.clml.2021.12.018","volume":"22","author":"B Moertl","year":"2022","unstructured":"Moertl, B., Dreyling, M., Schmidt, C., Hoster, E., Schoel, W., Bergwelt-Baildon, M., et al.: Inpatient treatment of relapsed\/refractory diffuse large B-cell lymphoma (r\/r DLBCL): A health economic perspective. Clinical Lymphoma Myeloma and Leukemia 22(7), 474\u2013482 (2022). https:\/\/doi.org\/10.1016\/j.clml.2021.12.018","journal-title":"Clinical Lymphoma Myeloma and Leukemia"},{"key":"1843_CR12","doi-asserted-by":"publisher","DOI":"10.57187\/s.3441","volume":"153","author":"M Trottmann","year":"2023","unstructured":"Trottmann, M., Blozik, E., Hilbig, M., LoVerdi, D., Pedruzzi, M., Scherer, T., et al.: Real-world expenditures and survival time after CAR-T treatment for large B-cell lymphoma in switzerland: A retrospective study using insurance claims data. Swiss Med. Wkly. 153, 3441 (2023). https:\/\/doi.org\/10.57187\/s.3441","journal-title":"Swiss Med. Wkly."},{"issue":"12","key":"1843_CR13","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0278950","volume":"17","author":"S Chacim","year":"2022","unstructured":"Chacim, S., Monjardino, T., Cunha, J., Medeiros, P., Redondo, P., Bento, M., et al.: Costs, effectiveness, and safety associated with chimeric antigen receptor (CAR) T-cell therapy: Results from a comprehensive cancer center. PLoS One 17(12), e0278950 (2022). https:\/\/doi.org\/10.1371\/journal.pone.0278950","journal-title":"PLoS One"},{"issue":"1","key":"1843_CR14","doi-asserted-by":"publisher","first-page":"738","DOI":"10.1080\/13696998.2024.2349472","volume":"27","author":"J Gatwood","year":"2024","unstructured":"Gatwood, J., Masaquel, A., Fox, D., Sheinson, D., James, C., Li, J., et al.: Real-world total cost of care by line of therapy in relapsed\/refractory diffuse large B-cell lymphoma. J. Med. Econ. 27(1), 738\u2013745 (2024). https:\/\/doi.org\/10.1080\/13696998.2024.2349472","journal-title":"J. Med. Econ."},{"issue":"2","key":"1843_CR15","doi-asserted-by":"publisher","first-page":"108","DOI":"10.3390\/cancers14040908","volume":"26","author":"S Costa","year":"2019","unstructured":"Costa, S., Scott, D., Steidl, C., Peacock, S., Regier, D.: Real-world costing analysis for diffuse large B-cell lymphoma in British Columbia. Curr. Oncol. 26(2), 108\u2013113 (2019). https:\/\/doi.org\/10.3390\/cancers14040908","journal-title":"Curr. Oncol."},{"issue":"10","key":"1843_CR16","doi-asserted-by":"publisher","first-page":"1266","DOI":"10.18553\/jmcp.2020.20095","volume":"26","author":"Q Huang","year":"2020","unstructured":"Huang, Q., Borra, S., Li, J., Wang, L., Shrestha, S., Sundaram, M., et al.: Time to next Treatment, health care resource Utilization, and costs associated with ibrutinib use among U.S. Veterans with chronic lymphocytic Leukemia\/Small lymphocytic lymphoma: A Real-World retrospective analysis. Journal of Managed Care & Specialty Pharmacy 26(10), 1266\u20131275 (2020). https:\/\/doi.org\/10.18553\/jmcp.2020.20095","journal-title":"Journal of Managed Care & Specialty Pharmacy"},{"key":"1843_CR17","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2024.1282323","volume":"14","author":"J Cho","year":"2024","unstructured":"Cho, J., Jang, S., Kang, D., Lee, E., Koh, H., Yoon, D., et al.: A nationwide analysis of the treatment patterns, survival, and medical costs in Korean patients with relapsed or refractory diffuse large B-cell lymphoma. Front. Oncol. 14, 1282323 (2024). https:\/\/doi.org\/10.3389\/fonc.2024.1282323","journal-title":"Front. Oncol."},{"key":"1843_CR18","doi-asserted-by":"publisher","first-page":"521","DOI":"10.2147\/CLEP.S341480","volume":"14","author":"C Petersen","year":"2022","unstructured":"Petersen, C., Jensen, K., Rosenzweig, M., von Osmanski, B., Ankarfeldt, M., Petersen, J.: Mapping outcomes and registries used in current Danish pharmacoepidemiological research. Clin. Epidemiol. 14, 521\u2013542 (2022). https:\/\/doi.org\/10.2147\/CLEP.S341480","journal-title":"Clin. Epidemiol."},{"issue":"4","key":"1843_CR19","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1177\/1403494815575193","volume":"43","author":"A Erlangsen","year":"2015","unstructured":"Erlangsen, A., Fedyszyn, I.: Danish nationwide registers for public health and health-related research. Scand J Public Health 43(4), 333\u2013339 (2015). https:\/\/doi.org\/10.1177\/1403494815575193","journal-title":"Scand J Public Health"},{"issue":"6","key":"1843_CR20","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0157999","volume":"11","author":"B Arboe","year":"2016","unstructured":"Arboe, B., El-Galaly, T., Clausen, M., et al.: The Danish National lymphoma registry: Coverage and data quality. PLoS One 11(6), e0157999 (2016). https:\/\/doi.org\/10.1371\/journal.pone.0157999","journal-title":"PLoS One"},{"key":"1843_CR21","unstructured":"Malignt Lymfom og CLL National \u00e5rsrapport: 1. januar 2022\u2013 31. december 2022. Dansk lymfom Database\/Dansk Kronisk Lymfatisk Leuk\u00e6mi Database. National \u00e5rsrapport 2022. (2022). Regionernes Kliniske Kvalitetsudviklingsprogram (www.rkkp.dk)."},{"issue":"7 Suppl","key":"1843_CR22","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1177\/1403494810387965","volume":"39","author":"C Pedersen","year":"2011","unstructured":"Pedersen, C.: The Danish civil registration system. Scand. J. Public. Health 39(7 Suppl), 22\u201325 (2011). https:\/\/doi.org\/10.1177\/1403494810387965","journal-title":"Scand. J. Public. Health"},{"issue":"7 Suppl","key":"1843_CR23","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1177\/1403494811401482","volume":"39","author":"E Lynge","year":"2011","unstructured":"Lynge, E., Sandegaard, J., Rebolj, M.: The Danish National Patient Register. Scand J Public Health 39(7 Suppl), 30\u201333 (2011). https:\/\/doi.org\/10.1177\/1403494811401482","journal-title":"Scand J Public Health"},{"issue":"7 Suppl","key":"1843_CR24","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1177\/1403494810394718","volume":"39","author":"J Andersen","year":"2011","unstructured":"Andersen, J., Olivarius, N., Krasnik, A.: The Danish National health service register. Scand. J. Public. Health. 39(7 Suppl), 34\u201337 (2011). https:\/\/doi.org\/10.1177\/1403494810394718","journal-title":"Scand. J. Public. Health"},{"issue":"7 Suppl","key":"1843_CR25","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1177\/1403494810394717","volume":"39","author":"H Kildemoes","year":"2011","unstructured":"Kildemoes, H., S\u00f8rensen, H., Hallas, J.: The Danish National prescription registry. Scand. J. Public. Health. 39(7 Suppl), 38\u201341 (2011). https:\/\/doi.org\/10.1177\/1403494810394717","journal-title":"Scand. J. Public. Health"},{"key":"1843_CR26","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1080\/14034940701271882","volume":"35","author":"N Hjollund","year":"2007","unstructured":"Hjollund, N., Larsen, F., Andersen, J.: Register-based follow-up of social benefits and other transfer payments: Accuracy and degree of completeness in a Danish interdepartmental administrative database compared with a population-based survey. Scand. J. Public. Health. 35, 497\u2013502 (2007). https:\/\/doi.org\/10.1080\/14034940701271882","journal-title":"Scand. J. Public. Health"},{"key":"1843_CR27","doi-asserted-by":"publisher","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","volume":"32","author":"B Cheson","year":"2014","unstructured":"Cheson, B., Fisher, R., Barrington, S., Cavalli, F., Schwartz, L., Zucca, E., et al.: Recommendations for initial evaluation, staging, and response assessment of hodgkin and non-Hodgkin lymphoma: The Lugano classification. J. Clin. Oncol. 32, 3059\u20133068 (2014). https:\/\/doi.org\/10.1200\/JCO.2013.54.8800","journal-title":"J. Clin. Oncol."},{"key":"1843_CR28","doi-asserted-by":"publisher","first-page":"2040","DOI":"10.1182\/blood-2010-03-276246","volume":"116","author":"B Coiffier","year":"2010","unstructured":"Coiffier, B., Thieblemont, C., Van Den Neste, E., Lepeu, G., Plantier, I., Castaigne, S., et al.: Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: A study by the groupe d\u2019etudes des lymphomes de l\u2019adulte. Blood 116, 2040\u20132045 (2010). https:\/\/doi.org\/10.1182\/blood-2010-03-276246","journal-title":"Blood"},{"issue":"1","key":"1843_CR29","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1182\/blood-2014-05-577189","volume":"125","author":"L Sehn","year":"2015","unstructured":"Sehn, L., Gascoyne, R.: Diffuse large B-cell lymphoma: Optimizing outcome in the context of clinical and biologic heterogeneity. Blood 125(1), 22\u201332 (2015). https:\/\/doi.org\/10.1182\/blood-2014-05-577189","journal-title":"Blood"}],"container-title":["The European Journal of Health Economics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10198-025-01843-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10198-025-01843-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10198-025-01843-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T03:46:15Z","timestamp":1779248775000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10198-025-01843-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,30]]},"references-count":29,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["1843"],"URL":"https:\/\/doi.org\/10.1007\/s10198-025-01843-x","relation":{},"ISSN":["1618-7598","1618-7601"],"issn-type":[{"value":"1618-7598","type":"print"},{"value":"1618-7601","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,30]]},"assertion":[{"value":"26 August 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 September 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Christian Graves Beck and Maya Friis Kj\u00e6rgaard are employees of Roche Pharmaceuticals a\/s. Tove Holm-Larsen and Martin Lucas J\u00f8rgensen were paid vendors to Roche Pharmaceuticals a\/s. S\u00f8ren Ramme Bro was a scientific consultant during the study, but did not receive any remuneration for this task.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests (disclosure)"}}]}}